A phase I/II study of golidocitinib, a selective JAK1 inhibitor, in refractory or relapsed peripheral T-cell lymphoma.

被引：0
|
作者：
Kim, Won Seog
Yoon, Dok Hyun
Song, Yuqin
Yang, Haiyan
Cao, Junning
Ji, Dongmei
Koh, Youngil
Jing, Hongmei
Eom, Hyeon Seok
Kwak, Jae-Yong
Lee, Won-Sik
Lee, Jong Seok
Shin, Ho-Jin
Jin, Jie
Wang, Mei
Li, Jingrun
Huang, Xubin
Deng, Xueyuan
Yang, Zhenfan
Zhu, Jun
机构：
[1] Samsung Med Ctr, Seoul, South Korea
[2] Univ Ulsan, Dept Oncol, Asan Med Ctr, Coll Med, Seoul, South Korea
[3] Peking Univ Canc Hosp & Inst, Beijing, Peoples R China
[4] Zhejiang Canc Hosp, Hangzhou, Peoples R China
[5] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[6] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea
[7] Peking Univ Third Hosp, Beijing, Peoples R China
[8] Natl Canc Ctr, Goyang, South Korea
[9] Chonbuk Natl Univ Hosp, Jeonju Si, South Korea
[10] Inje Univ, Busan Paik Hosp, Busan, South Korea
[11] Seoul Natl Univ, Bundang Hosp, Seongnam, South Korea
[12] Pusan Natl Univ Hosp, Pusan, South Korea
[13] Zhejiang Univ, Coll Med, Affiliated Hosp 1, Hangzhou, Peoples R China
[14] Dizal Pharmaceut, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7563
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Preliminary Biomarker Data from a Phase 1/2 Study of Golidocitinib Demonstrates Targeting JAK/STAT Pathway to Treat Peripheral T-Cell Lymphoma
    Song, Yuqin
    Kim, Won-Seog
    Yoon, Dok-Hyun
    Yang, Haiyan
    Cao, Junning
    Ji, Dongmei
    Koh, Youngil
    Jing, Hongmei
    Eom, Hyeon-Seok
    Kwak, Jae-Yong
    Lee, Won-Sik
    Lee, Jong-Seok
    Shin, Ho-Jin
    Jin, Jie
    Wang, Mei
    Li, Jingrun
    Zhu, Jun
    BLOOD, 2022, 140 : 6545 - 6546
  • [42] Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results
    Rai, Shinya
    Kim, Won Seog
    Ando, Kiyoshi
    Choi, Ilseung
    Izutsu, Koji
    Tsukamoto, Norifumi
    Yokoyama, Masahiro
    Tsukasaki, Kunihiro
    Kuroda, Junya
    Ando, Jun
    Hidaka, Michihiro
    Koh, Youngil
    Shibayama, Hirohiko
    Uchida, Toshiki
    Yang, Deok Hwan
    Ishitsuka, Kenji
    Ishizawa, Kenichi
    Kim, Jin Seok
    Lee, Hong Ghi
    Minami, Hironobu
    Eom, Hyeon Seok
    Kurosawa, Mitsutoshi
    Lee, Jae Hoon
    Lee, Jong Seok
    Lee, Won Sik
    Nagai, Hirokazu
    Shindo, Takero
    Yoon, Dok Hyun
    Yoshida, Shinichiro
    Gillings, Mireille
    Onogi, Hiroshi
    Tobinai, Kensei
    HAEMATOLOGICA, 2023, 108 (03) : 811 - 821
  • [43] Selective PI3K δ Inhibitor Parsaclisib Combined with HDAC Inhibitor Chidamide in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma: Preliminary Results of a Phase Ib/II Study
    Yan, Zheng
    Yao, Shuna
    Zhao, Shuang
    Wang, Haiying
    Chu, Junfeng
    Xu, Yuanlin
    Zhang, Jiuyang
    Zhang, Lina
    Lin, Quande
    Liang, Lijie
    Wang, Ping
    Li, Wenyong
    Teng, Xiaolu
    Yao, Zhihua
    Liu, Yanyan
    BLOOD, 2023, 142
  • [44] Phase II study of pentostatin in relapsed T-cell lymphoma
    D'Orazio, AI
    Fisher, MD
    CLINICAL LYMPHOMA, 2002, 2 (04): : 206 - 207
  • [45] Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma
    Campbell, Peter
    Thomas, Christan M.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2017, 23 (02) : 143 - 147
  • [46] Emerging Therapies in Relapsed and Refractory Peripheral T-Cell Lymphoma
    Bachow, Spencer H.
    O'Connor, Owen A.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (12) : 837 - 846
  • [47] Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma
    Rashidi, Armin
    Cashen, Amanda F.
    FUTURE ONCOLOGY, 2015, 11 (11) : 1659 - 1664
  • [48] Therapeutic Advances in Relapsed and Refractory Peripheral T-Cell Lymphoma
    Stuver, Robert
    Moskowitz, Alison J.
    CANCERS, 2023, 15 (03)
  • [49] Therapeutic options in relapsed or refractory peripheral T-cell lymphoma
    Coiffier, Bertrand
    Federico, Massimo
    Caballero, Dolores
    Dearden, Claire
    Morschhauser, Franck
    Jaeger, Ulrich
    Truemper, Lorenz
    Zucca, Emanuele
    da Silva, Maria Gomes
    Pettengell, Ruth
    Weidmann, Eckhart
    d'Amore, Francesco
    Tilly, Herve
    Zinzani, Pier Luigi
    CANCER TREATMENT REVIEWS, 2014, 40 (09) : 1080 - 1088
  • [50] Pilot study of sorafenib in relapsed or refractory peripheral and cutaneous T-cell lymphoma
    Gibson, Juliet Fraser
    Foss, Francine
    Cooper, Dennis
    Seropian, Stuart
    Irizarry, Diana
    Barbarotta, Lisa
    Lansigan, Frederick
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 167 (01) : 141 - 144
12345